Market Overview

Thomas J. Henry Injury Attorneys Investigating Allegations of Kidney Failure in BMS-986094 Clinical Trials

Share:

Thomas J. Henry Injury Attorneys is currently investigating new injuries, including kidney failure, alleged in BMS-986094 clinical trial patients.

San Antonio, Texas (PRWEB) May 20, 2013

Thomas J. Henry Injury Attorneys is investigating allegations of renal failure, some resulting in the need for dialysis, in patients enrolled in clinical trials for the Bristol Myers Squibb Hepatitis C drug BMS-986094.

Thomas J. Henry Injury Attorneys is representing victims across the United States who suffered injuries believed to be caused by the BMS-986094 clinical trials. According to a statement released on August 23, 2012 by Bristol Myers Squibb, the trials were ended early when a study patient died of heart failure and eight others were hospitalized for heart and kidney toxicity and other injuries.

Injuries Reported in BMS-986094 Trials:

  •     Fatigue
  •     Nausea/vomiting
  •     Shortness of breath
  •     Decreased urine production
  •     Kidney damage
  •     Renal Failure
  •     Swelling of the legs
  •     Feelings of anxiety
  •     Heart palpitations
  •     Chest pain
  •     Abnormal heart rhythm
  •     Valve inflammation
  •     Cardiomyopathy
  •     Heart damage
  •     Heart attack
  •     Heart failure
  •     Death

Locations of the BMS-986094 trials:

  •     Montgomery, AL
  •     Augusta, GA
  •     Asheville, NC
  •     Tulsa, OK
  •     Arlington, TX
  •     Hoover, AL
  •     Anaheim, CA
  •     La Jolla, CA
  •     San Diego, CA
  •     San Francisco, CA
  •     Orlando, FL
  •     Atlanta, GA
  •     New York, NY
  •     Portland, OR
  •     Austin, TX
  •     San Antonio, TX
  •     Fairfax, VA
  •     Newport News, VA
  •     Seattle, WA

Thomas J. Henry Injury Attorneys continues to investigate injury claims related to BMS-986094 and is accepting cases related to heart and kidney injuries in BMS-986094 patients.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10750820.htm

View Comments and Join the Discussion!